13,487 Merck & Co., Inc. $MRK Shares Sold by Generali Investments Management Co LLC

Key Points

• Generali Investments Management cut its Merck stake by 23% in the third quarter, selling 13,487 shares and retaining 45,260 shares valued at approximately $6.6 million. Institutional investors collectively own 76.07% of MRK.
• Merck reported better-than-expected quarterly revenue of $16.61 billion and raised attention around its oncology pipeline, including positive Keytruda-related skin-cancer data and upcoming Phase 3 results.
• Analysts maintain a generally favorable outlook, with a consensus rating of “Moderate Buy” and an average price target of $151.92. However, shares have rallied more than 38% in 2026, and the elevated valuation increases sensitivity to disappointing trial results.

Generali Investments Management Co LLC decreased its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 23.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 45,260 shares of the company's stock after selling 13,487 shares during the quarter. Merck & Co., Inc. comprises about 1.3% of Generali Investments Management Co LLC's portfolio, making the stock its 18th largest holding. Generali Investments Management Co LLC's holdings in Merck & Co., Inc. were worth $6,577,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of MRK. Susquehanna Fundamental Investments LLC bought a new stake in Merck & Co., Inc. in the second quarter worth $11,470,000. Russell Investments Group Ltd. lifted its position in Merck & Co., Inc. by 2.0% during the second quarter. Russell Investments Group Ltd. now owns 2,578,024 shares of the company's stock valued at $331,931,000 after purchasing an additional 51,393 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Merck & Co., Inc. by 7.0% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,184,340 shares of the company's stock valued at $794,577,000 after purchasing an additional 402,011 shares during the last quarter. Talon Private Wealth LLC bought a new position in Merck & Co., Inc. during the second quarter valued at $995,000. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Merck & Co., Inc. by 12.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,073,176 shares of the company's stock worth $266,403,000 after buying an additional 227,589 shares in the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported promising skin-cancer trial results involving Keytruda and a personalized mRNA vaccine. Positive clinical data could strengthen confidence in Merck’s oncology franchise and support longer-term growth. Merck reports promising skin cancer trial results
• Positive Sentiment: Merck is scheduled to present first-time pivotal Phase 3 oncology results at ESMO 2026, including melanoma and endometrial-cancer programs, alongside an oncology investor event. The disclosures may demonstrate progress in replacing or extending revenue from existing cancer therapies. Merck ESMO 2026 oncology pipeline preview
• Positive Sentiment: Merck’s continued uptrend has encouraged options traders to consider bullish strategies, indicating that some market participants expect further gains. Options activity, however, can amplify volatility and does not by itself change the company’s fundamentals. Merck bullish options strategy
• Neutral Sentiment: Merck’s investment narrative has shifted toward oncology and other growth opportunities as investors look beyond challenges affecting Gardasil, particularly in China. The strategy could improve diversification, but execution and pipeline commercialization remain key.
• Neutral Sentiment: Merck is being compared favorably with other pharmaceutical companies on dividend sustainability and cash generation, though the articles do not identify a major new dividend announcement. Merck versus Amgen dividend comparison
• Negative Sentiment: After rising more than 38% in 2026, Merck trades at a substantially higher forward earnings multiple than in late 2025. Analysts warn that the market may already be pricing in significant pipeline success, leaving less room for upside and greater sensitivity to disappointing trial data. Merck valuation and rally analysis

Wall Street Analysts Forecast Growth

MRK has been the topic of a number of research reports. Morgan Stanley reduced their target price on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an "overweight" rating on the stock in a report on Wednesday, October 7th. Cantor Fitzgerald increased their price target on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the company a "neutral" rating in a report on Thursday, October 8th. Guggenheim lifted their price target on Merck & Co., Inc. from $146.00 to $170.00 and gave the stock a "buy" rating in a research report on Tuesday, September 8th. Berenberg Bank boosted their price objective on Merck & Co., Inc. from $127.00 to $137.00 and gave the stock a "hold" rating in a research note on Friday, September 11th. Finally, The Goldman Sachs Group upped their price objective on Merck & Co., Inc. from $140.00 to $160.00 and gave the company a "buy" rating in a research report on Friday, August 21st. Seventeen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, Merck & Co., Inc. presently has an average rating of "Moderate Buy" and an average price target of $151.92.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David Williams sold 52,847 shares of the business's stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president directly owned 31,716 shares of the company's stock, valued at $4,084,069.32. The trade was a 62.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Richard R. Deluca sold 20,784 shares of the company's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the completion of the transaction, the executive vice president owned 134,703 shares in the company, valued at $17,569,312.29. This represents a 13.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 228,238 shares of company stock valued at $29,977,783. Company insiders own 0.17% of the company's stock.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $146.01 on Monday. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The firm has a market capitalization of $360.22 billion, a P/E ratio of 116.81, a price-to-earnings-growth ratio of 6.74 and a beta of 0.21. Merck & Co., Inc. has a 1-year low of $82.01 and a 1-year high of $156.92. The company's 50-day moving average is $145.60 and its 200 day moving average is $129.31.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The business had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. During the same quarter in the previous year, the business earned $2.13 earnings per share. The company's revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Research analysts forecast that Merck & Co., Inc. will post 2.66 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were paid a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.'s payout ratio is currently 272.00%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck's principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.